Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 2/20 | 0.36 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25940770 | 0.91 | TDP1 (0.42) | CA1CA2TDP1DRD2CA12 | |
| SCHEMBL1509985 | 0.89 | SMN1; SMN2 (0.42) | DRD2HPGDHTTSMN1; SMN2CYP3A4 | |
| SCHEMBL1510026 | 0.89 | SMN1; SMN2 (0.42) | DRD2HPGDHTTSMN1; SMN2CYP3A4 | |
| SCHEMBL16995749 | 0.87 | DRD2 (0.39) | CA1CA2TDP1DRD2MEN1 | |
| SCHEMBL17589281 | 0.85 | CA12 (0.38) | CA1CA2TDP1CA12CA9 | |
| SCHEMBL22402873 | 0.85 | TDP1 (0.47) | CA1CA2TDP1DRD2CA12 | |
| SCHEMBL3474501 | 0.85 | TDP1 (0.47) | CA1CA2TDP1DRD2CA12 | |
| SCHEMBL25129444 | 0.85 | TLR2 (0.38) | CA1CA2TDP1CA12CA9 | |
| SCHEMBL10071724 | 0.85 | CA1 (0.42) | CA1CA2TDP1DRD2MEN1 | |
| SCHEMBL12317123 | 0.85 | TLR2 (0.38) | CA1CA2TDP1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179446-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7052673-B2 | Pharmaceuticals for the imaging of angiogenic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | LANTHEUS MEDICAL IMAGING, INC. | 2006-01-05 | — | — | US | disclosed |
| US-20050118100-A9 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2005-06-02 | — | — | US | disclosed |
| EP-1068224-B1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6800273-B2 | ANTICANCER AGENTS; ANGIOGENOSIS INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20030180305-A1 | Pharmaceuticals for the imaging of angiogenic disorders | LANTHEUS MEDICAL IMAGING, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6537520-B1 | Diagnosis and treatment of cancer; kit containing compound having peptide or peptidomimetic functionality that binds to a alpha v beta 3 receptor linked to a chelator | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-25 | — | — | US | disclosed |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | CARPENTER ALAN P (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-03 | — | — | US | disclosed |
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050118100-A9 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | CA1 1947/4885CA2 1691/4885TDP1 4609/4885 |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | CA1 1947/4885CA2 1691/4885TDP1 4609/4885 |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | VEGFA, FLT4, FLT1 | CA1 3033/4885CA2 1859/4885TDP1 4448/4885 |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | FLT4, VEGFA, FLT1 | CA1 4004/4885CA2 2952/4885TDP1 4525/4885 |
| US-20030180305-A1 | Pharmaceuticals for the imaging of angiogenic disorders | VEGFA, FLT4, FLT1 | CA1 3033/4885CA2 1859/4885TDP1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.